Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more
Seoul Pharma Co. Ltd (018680) - Total Liabilities
Latest total liabilities as of September 2025: ₩32.70 Billion KRW
Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has total liabilities worth ₩32.70 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Seoul Pharma Co. Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Seoul Pharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Seoul Pharma Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Seoul Pharma Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MONOLITHIC POWER (NQG.SG)
STU:NQG
|
Germany | €503.05 Million |
|
Censof Holdings Bhd
KLSE:5195
|
Malaysia | RM29.98 Million |
|
Concejo AB (publ)
ST:CNCJO-B
|
Sweden | Skr187.80 Million |
|
Property Perfect Public Company Limited
BK:PF
|
Thailand | ฿32.61 Billion |
|
Fancamp Exploration Ltd.
PINK:FNCJF
|
USA | $7.70 Million |
|
Paterson Resources Ltd
AU:PSL
|
Australia | AU$40.72K |
|
Movano Inc
NASDAQ:MOVE
|
USA | $7.26 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Seoul Pharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seoul Pharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seoul Pharma Co. Ltd (2012–2024)
The table below shows the annual total liabilities of Seoul Pharma Co. Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩31.45 Billion | +27.11% |
| 2023-12-31 | ₩24.74 Billion | -8.39% |
| 2022-12-31 | ₩27.01 Billion | -37.62% |
| 2021-12-31 | ₩43.29 Billion | +19.48% |
| 2020-12-31 | ₩36.23 Billion | -14.62% |
| 2019-12-31 | ₩42.44 Billion | +5.43% |
| 2018-12-31 | ₩40.25 Billion | +21.70% |
| 2017-12-31 | ₩33.08 Billion | -34.47% |
| 2016-12-31 | ₩50.47 Billion | +2.70% |
| 2015-12-31 | ₩49.15 Billion | +2.65% |
| 2014-12-31 | ₩47.88 Billion | +22.23% |
| 2013-12-31 | ₩39.17 Billion | +10.99% |
| 2012-12-31 | ₩35.29 Billion | -- |